Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Elkem ASA – Exercise of share options under share incentive programme

Oslo, 28 April 2022 Option holders under Elkem ASA's ("Elkem" or the "Company", OSE ticker code: "ELK") share incentive programme have today exercised a total 290,000 options, of which 200,000 options have an exercise price of NOK 23.53 per share and 90,000 options have an exercise price of NOK 19.10 per share. The exercised options will be settled by delivery of Elkem’s shareholding of own shares. Following the transfer, the Company will hold 5,715,636 own shares. The primary insider listed below has transferred his rights to receive the new shares to a third party in return for a

Newsletter April 2022 – Progress in Cline’s cell lab and in the stem cell therapy field

Spring has arrived in Gothenburg, and the Cline is excited to bring you some exciting news and updates from our teamThe first stage of Ex-vivo testing completed   Early this month, Cline announced that the first stage of our ex-vivo experiments was carried out with encouraging performance. This newsletter will take a deeper look at what's happening in our labs and what these tests mean for StemCART.  These experiments, which began in January 2022, are an important milestone for the StemCART project and will push the project into the next development stage. In these tests, Cline

Lytix Biopharma to present at the American Society of Clinical Oncology (ASCO) Annual Meeting

Oslo, Norway, April 28, 2022 – Lytix Biopharma AS (Lytix), a clinical-stage company with an in situ vaccination technology platform targeting cancer indications, today announces that its abstract has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago June 3-7, 2022. Title: LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma.Presenter: Morten Nielsen, MD | National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital,

Invitation to presentation of Addtech's Year-end report on May 17, at 10.00 a.m (CEST)

Welcome to a conference call regarding Addtech's Year-end report on May 17 at 10.00 a.m (CEST). The conference is aimed at analysts, the media and investors and will be held in English. The presentation will be hosted by CEO Niklas Stenberg and CFO Malin Enarson. The presentation material will be available in advance here: https://www.addtech.com/investors-and-media/presentations It will also be possible to follow the presentation on the web, see link below. The webcast will also be available afterwards via the same link. For participation in the conference:Phone:Sweden: +46 8 566

Alma Media has completed the sale of its minority share in Bolt Group Oy

Alma Media Corporation                           Press release                                         28 April 2022 ALMA MEDIA HAS COMPLETED THE SALE OF ITS MINORITY SHARE IN BOLT GROUP OY Alma Media has completed the sale of its minority share in the Finnish staffing company Bolt Group Oy. The transaction was announced on February 18, 2022 and it was completed after inter alia the approval of the Finnish Competition and Consumer Authority on April 1, 2022. Alma Career Ltd, a subsidiary of Alma Media Corporation, sold all of its share capital, representing 21.05% of the total

Improved controller for clinical trials results in six-month delay

Press release 28 April, 2022 Realheart has decided to equip patients in the first clinical trial with the full version of the controller – a kind of remote control – instead of a simpler version as previously envisaged. This will benefit patients and shorten the overall development time of the controller but will delay the human trial by six months, now set to begin in the first half of 2024 instead of the second half of 2023.''Our goal is an artificial heart that allows the user to lead a good life with great freedom of movement. This also applies to the patients participating in our

Höegh LNG: Sustainability Report for 2021

Hamilton, Bermuda, 28 April 2022 - Höegh LNG Holdings Ltd. ("Höegh LNG") has today published its first separate sustainability report. The report describes Höegh LNG’s achievements in 2021 as well as the 2030 ambitions and how Höegh LNG aims to achieve these in the years to come.Sustainability is high on Höegh LNG’s agenda, and the summary of the overall work has created a solid foundation to deliver sustainable values for our customers, employees, and company. “We make decisions every day, that have an effect across our value chain: they affect people, customers, and suppliers, as well

NeoDynamics publishes supplementary document introducing listing on Nasdaq First North Growth Market

NeoDynamics AB (publ)  (NeoDynamics or "the Company") received a conditional approval for admission to trading of the Company's shares on the Nasdaq First North Growth Market (“Nasdaq First North”) on April 12, 2022. For this reason, the company has published a Supplementary document on its website in accordance with Nasdaq First North Growth Markets' listing requirements.   The Supplementary document can be found on the Company's website: SV: https://www.neodynamics.com/sv-se/aktien EN: https://www.neodynamics.com/en-gb/shares DE: https://www.neodynamics.com/de-de/aktien

Etteplan’s January-March 2022 interim report to be published on May 5, 2022

ETTEPLAN OYJ, Investor News, April 28, 2022, at 1.00 p.m.   Etteplan’s January-March 2022 interim report to be published on May 5, 2022  Etteplan Oyj will publish its January-March 2022 interim report on Thursday May 5, 2022 at approximately 1.00 p.m. Finnish time (EEST). The release and related presentation material will be available in Finnish and in English on the Company’s website at www.etteplan.com  after the publishing. Conference call and live webcast  Etteplan’s President and CEO Juha Näkki will present the Company’s result for

Interim report January – March 2022

Summary, January – March 2022· Rental income increased 15 per cent to SEK 983 million (857). · Profit from property management increased 19 per cent to SEK 572 million (481). · Changes in the value of investment properties amounted to SEK 1,734 million (589) and changes in the value of financial instruments to SEK -3 million (40). · Profit after tax for the period increased to SEK 1,934 million (935). · The market value of the properties amounted to SEK 79,987 million (65,528). · During the period, SEK 942 million (762) was invested in the existing property portfolio. ·

Interim report January - March 2022

JANUARY – MARCH 2022 · Sales increased by 36 percent and amounted to 5,173 MSEK (3,810). · EBIT increased by 10 percent to 775 MSEK (704). · EBIT-margin amounted to 15.0 percent (18.5). · Profit after tax increased by 12 percent to 600 MSEK (534). · Earnings per share increased by 12 percent to 1.74 SEK (1.55). · Operating cash flow amounted to 103 MSEK (433). Strong result in a continued challenging environmentDespite major challenges in the supply chain with raw material shortages, transport problems, and increased prices on both raw materials and energy costs, we

Invitation to Ferronordic’s investor presentation 12 May 2022

Ferronordic’s interim report for the first quarter 2022 will be published on 12 May 2022 at 07:30 CET. A presentation of the report will be held the same day at 10:00 CET.Ferronordic’s interim report for the first quarter 2022 will be published on 12 May 2022 at 07.30 CET and will be accessible at www.ferronordic.com. Ferronordic invites investors, analysts and the media to a presentation where Lars Corneliusson, CEO, and Erik Danemar, CFO, comment on the report. The presentation will be held on 12 May 2022 at 10:00 CET and can be followed via telephone conference or audiocast.   The

Nordax Bank AB (publ) publishes the annual report and the sustainability report for 2021

The reports are available at https://www.nordaxgroup.com/investors For further information, please contact: Patrick McArthur, CFO, Nordax Tel: +46 760 32 69 70 Email: ir@nordax.se About Nordax Nordax Bank is a leading specialist bank in Northern Europe with strong owners in the form of Nordic Capital Fund IX, Nordic Capital Fund VIII and Sampo. We currently have a little under 2 million private customers, of which just under 1.2 million are credit card customers, in the Nordic countries, Spain, Germany and the Netherlands. We are a specialist bank that through

Nordax Holding AB (publ) publishes the annual report and the sustainability report for 2021

The reports are available at https://www.nordaxgroup.com/investors For further information, please contact: Patrick McArthur, CFO, Nordax Tel: +46 760 32 69 70 Email: ir@nordax.se About Nordax Holding Nordax Holding is a holding company that owns Nordax Bank through Nordax Group. Nordax Bank is a leading specialist bank in Northern Europe with strong owners in the form of Nordic Capital Fund IX, Nordic Capital Fund VIII and Sampo. We currently have a little under 2 million private customers, of which just under 1.2 million are credit card customers, in the Nordic

Interim report January- March 2022

In the interim report for January to March, VBG Group reports record-high sales for the Group.First quarter 2022 · Consolidated sales increased by 28.2% to SEK 1,155.5 M (901.4). · Adjusted for exchange rate changes and acquired volume between the years, organic growth was 17.4%. · Operating profit (EBITA) amounted to SEK 164.1 M (149.6). · The operating margin (EBITA) was 14.2% (16.6). · Profit after financial items amounted to SEK 147.9 M Comment from VBG Group´s President & CEO, Anders Birgersson  In the first quarter of 2022, VBG Group achieved quarterly sales of

Scandic to open third hotel in Tromsø

Scandic Hotels has signed a long-term lease agreement with property owner Totaleiendom AS for a new hotel with 305 rooms on 12 floors in the new Vervet area in Tromsø, Norway. Scandic already operates two hotels in the city with a total of 390 hotel rooms. The new hotel, which is expected to open in 2025, will be an important addition to meet the demand from the growing leisure segment.The hotel will be located in the new Vervet district that is currently being built on the waterfront in downtown Tromsø. It will feature 305 hotel rooms, a restaurant, a sky bar, a rooftop terrace and meeting

MidCo Infrastructure Logistics AB (publ) publishes approved bond prospectus in anticipation of listing of its bonds on Nasdaq Stockholm

MidCo Infrastructure Logistics AB (publ) (the “Company”) issued senior secured callable floating rate bonds in an initial amount of SEK 300 million on 12 April 2021 and in a subsequent amount of SEK 200 million on 2 February 2022 (the “Bonds”).For the purpose of the listing of the Bonds, the Company has prepared a prospectus that has today been approved by the Swedish Financial Supervisory Authority (Sw: Finansinspektionen). The prospectus is available on the Company’s corporate website: www.infralogistic.se.   Admission to trading of the Bonds on Nasdaq Stockholm is expected to

Vattenfall's Annual General Meeting 2022

Vattenfall AB's Annual General Meeting (AGM) was held on Thursday April 28. Among other things, the AGM decided on a dividend payout of SEK 23.414 billion to its owner, the Swedish State. Also, Mats Granryd was elected new Chairman of the Board.Vattenfall’s owner was represented at the AGM voting by  Christine Leandersson, Senior Adviser at the Ministry of Enterprise and Innovation. The owner was also represented by Stina Billinger, State Secretary, who gave a speech. Annual General Meeting decisions: Adoption of balance sheet and income statement The AGM adopted the income and

Instalco wins assignment at Västervik Hospital

The Instalco company, Ventpartner, has signed an agreement with Skanska for the ventilation work in conjunction with construction of a new building for specialist psychiatry at Västervik Hospital. It is a partnering project involving Skanska, Region Kalmar and other partners.The assignment for Ventpartner has an order value of around SEK 47 million, including the design and planning that has been done. It will house premises for forensic psychiatry, round-the-clock care and open adult psychiatry. The building size will be approximately 24,500 sq. m. and it will have 6 floors. “Being a

BerGenBio ASA: Minutes from the Annual General Meeting

Bergen, Norway, 28 April 2022 – Annual general meeting of BerGenBio ASA was virtually held today 28 April 2022 at 10.00 CET.   All proposals were resolved as presented in the notice convening the annual general meeting distributed on 7 April 2022, as further set out in the minutes from the annual general meeting attached hereto and available at https://www.bergenbio.com/investors/general-meetings/.   For further information, please contact:   Martin Olin CEO, BerGenBio ASA ir@bergenbio.com   Rune Skeie CFO, BerGenBio ASA rune.skeie@bergenbio.com

OssDsign publishes Annual Report 2021

OssDsign AB (publ) announces that the Annual Report for 2021 is now available as a pdf on the company's website www.ossdsign.com. A pdf version is also attached to this press release.For further information, please contact:Morten Henneveld, CEO, OssDsign ABTel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com Certified Adviser:Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se. About OssDsign:OssDsign is a developer and global

Planmeca Emerald® intraoral scanner data can now be used for producing SomnoDent® sleep apnea devices

Planmeca is happy to announce an easy workflow for ordering SomnoDent® oral appliances from SomnoMed using the Planmeca Emerald® intraoral scanners and the Planmeca Romexis® Cloud service. SomnoMed manufactures the world’s leading OAT (Open Airway Therapy) oral appliances for sleep apnea treatment under the SomnoDent® brand. By establishing a seamlessly integrated workflow for ordering SomnoDent oral appliances directly from the Planmeca Romexis® software, Planmeca extends the range of solutions available for Planmeca Emerald® users for sleep apnea treatments. The Planmeca

Posiva's Annual Report 2021 has been published

During 2021, Posiva's EKA project, comprising of the construction of an encapsulation plant and an underground final disposal facility for the disposal of spent nuclear fuel, has progressed as planned.In May, the excavation of the first five actual deposition tunnels – which are accessed via the central tunnels – was started in ONKALO at a depth of approximately 430 metres. At the end of 2021, approximately half of the excavation work was completed. In December, the encapsulation plant reaching its rooftop height was celebrated.  A significant event in terms of the project preparation

There are no items matching the current filter
There are no more items matching the current filter
Back to top